背景:牛皮癣(Pso)是一种常见的影响皮肤的慢性炎症性疾病,两性,和所有年龄。它可能与其他慢性炎症性肌肉骨骼疾病和某些药物有关,包括肿瘤坏死因子α(TNFα)拮抗剂。
方法:使用SB-4(Benepali)治疗一名64岁的血清阴性类风湿关节炎(RA)患者,依那西普生物仿制药50mg/周皮下。他对治疗反应良好,但一年后,他出现红斑性皮疹,主要影响双手的手掌。皮肤活检显示与Pso相符的图片。SB-4停产了,加上局部类固醇治疗,皮肤损伤消失。这是与SB-4治疗相关的牛皮癣皮肤病变的唯一病例。
结论:因此,我们回顾并讨论了与SB-4和其他抗TNFα生物类似物相关的Pso病例的相关文献。治疗抗TNFα生物类似物患者的风湿病学家应该意识到并认识到这些并发症。
BACKGROUND: Psoriasis (Pso) is a common chronic inflammatory disease affecting the skin, both sexes, and all ages. It can be associated with other chronic inflammatory musculoskeletal disorders and certain drugs, including tumor necrosis factor α (TNFα) antagonists.
METHODS: A 64-year-old man with seronegative rheumatoid arthritis (RA) refractory to leflunomide and prednisone was treated with SB-4 (Benepali), an etanercept biosimilar 50mg/week subcutaneously. He responded well to the treatment, but a year later, he developed erythematous skin eruptions affecting mainly in the palms of both hands. Skin biopsy showed a picture compatible with Pso. SB-4 was discontinued, and the skin lesions disappeared with the addition of topical steroid therapy. This is the only case of psoriatic skin lesions associated with SB-4 treatment.
CONCLUSIONS: Thus, we review and discuss the relevant literature of Pso cases related to SB-4 and other anti-TNFα biosimilars. Rheumatologists dealing with patients on anti-TNFα biosimilars should be aware of and recognize these complications.